So far, DNMT inhibitors such as azacitidine and decitabine have been approved for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) [61,62]. The gene discussed is DNMT1; the disease is myelodysplastic syndrome.